Luncheon Symposium

This educational symposium puts the focus on changing the trajectory of the prostate cancer patient journey. It is structured around two core segments that explore optimized treatment approaches for non-metastatic (nmHSPC), and metastatic, hormone-sensitive prostate cancer (mHSPC). Featuring case-based learning, this practical symposium on these pertinent topics expounds current evidence to guide clinical decision-making in both settings.

In nmHSPC, the primary therapeutic goals are delaying disease progression and enhancing long-term outcomes. Central to this discussion is a case presentation of a patient with biochemical recurrence and no evidence of metastases. The faculty will compare currently-available treatment options.

Recently released EMBARK results will be discussed, highlighting the efficacy of enzalutamide-based approaches in this patient population. The engaging discussions will be centred around benefits and risks, such as those associated with androgen deprivation therapy (ADT) and enzalutamide. Further, the faculty will aim to provide insight into how therapy can be tailored (patient preference and tolerability), balancing clinical efficacy with a patient-centered approach.

This symposium will also address treatment intensification strategies in mHSPC, underscoring the importance of early combination therapy to extend progression-free survival (PFS) and overall survival (OS). The mHSPC discussions will be centered around new long-term data from pertinent studies.

Based on an mHSPC patient the discussions will focus around topics pertinent to day-to-day patient care, including the use of combination therapy, the implications of disease volume (low vs high), the presence of visceral vs bone metastases, and prior chemotherapy exposure.

By the end of the session, participants should have a clearer understanding of the latest treatment paradigms for HSPC patients, and an appreciation of real world considerations in the application of data to practice. Evidence-based clinical care, especially in the hormone sensitive space, can confer improved survival and treatment outcomes.

*Please note that hormone sensitive prostate cancer (HSPC) may be referred to as castration resistant prostate cancer (CSPC) in some countries